Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
- E. Gabriela Chiorean
- , H. I. Hurwitz
- , R. B. Cohen
- , J. D. Schwartz
- , R. P. Dalal
- , F. E. Fox
- , L. Gao
- , C. J. Sweeney
Research output: Contribution to journal › Article › peer-review
75
Scopus
citations